{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderately+to+Severely+Active+Ulcerative+Colitis&page=3", "query": { "condition": "Moderately to Severely Active Ulcerative Colitis", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 120, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderately+to+Severely+Active+Ulcerative+Colitis&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderately+to+Severely+Active+Ulcerative+Colitis&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T06:15:02.656Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03662542", "title": "A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Guselkumab Dose 1", "type": "DRUG" }, { "name": "Guselkumab Dose 2", "type": "DRUG" }, { "name": "Golimumab Dose 1", "type": "DRUG" }, { "name": "Golimumab Dose 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 214, "start_date": "2018-11-20", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 14, "location_summary": "San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662542" }, { "nct_id": "NCT02954159", "title": "Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2017-05-18", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954159" }, { "nct_id": "NCT03945188", "title": "Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrasimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arena Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 433, "start_date": "2019-06-13", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 67, "location_summary": "Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945188" }, { "nct_id": "NCT04033445", "title": "A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1064, "start_date": "2019-09-26", "completion_date": "2027-07-16", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 52, "location_summary": "Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033445" }, { "nct_id": "NCT02065622", "title": "Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 952, "start_date": "2014-03-27", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 42, "location_summary": "Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065622" }, { "nct_id": "NCT07577856", "title": "A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "JNJ-78934804", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 644, "start_date": "2026-05-23", "completion_date": "2030-10-16", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 20, "location_summary": "Anaheim, California • Chula Vista, California • Los Alamitos, California + 17 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07577856" }, { "nct_id": "NCT00488631", "title": "An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Golimumab 50 mg", "type": "BIOLOGICAL" }, { "name": "Golimumab 100 mg", "type": "BIOLOGICAL" }, { "name": "Golimumab 200 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1228, "start_date": "2007-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 96, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Merced", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488631" }, { "nct_id": "NCT03596645", "title": "A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Golimumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 84, "start_date": "2018-10-29", "completion_date": "2027-02-01", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 12, "location_summary": "San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03596645" }, { "nct_id": "NCT07665723", "title": "An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Active Ulcerative Colitis" ], "interventions": [ { "name": "Afimkibart", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Vitamin K", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2026-06-29", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 3, "location_summary": "Chula Vista, California • Miami, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07665723" }, { "nct_id": "NCT07185009", "title": "A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Duvakitug", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 751, "start_date": "2026-01-16", "completion_date": "2033-04-28", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-04T06:15:02.656Z", "location_count": 28, "location_summary": "Tucson, Arizona • Coronado, California • Murrieta, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Victorville", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07185009" } ] }